INS and metabolic dysfunction-associated steatotic liver disease: As discussed, newly identified co-factors (epigenetic modifiers) and/or partners (adipose HSL) in these tissues may also represent potential therapeutic strategies for NAFLD and/or for improving systemic insulin sensitivity.